Edesa Biotech, Inc.

NasdaqCM EDSA

Edesa Biotech, Inc. Market Capitalization on January 14, 2025: USD 5.51 M

Edesa Biotech, Inc. Market Capitalization is USD 5.51 M on January 14, 2025, a -62.51% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Edesa Biotech, Inc. 52-week high Market Capitalization is USD 17.86 M on February 14, 2024, which is 223.88% above the current Market Capitalization.
Edesa Biotech, Inc. 52-week low Market Capitalization is USD 5.51 M on January 14, 2025, which is 0.00% below the current Market Capitalization.
Edesa Biotech, Inc. average Market Capitalization for the last 52 weeks is USD 12.87 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: EDSA

Edesa Biotech, Inc.

CEO	Dr. Pardeep Nijhawan FRCPC, M.D.
IPO Date	June 21, 2010
Location	Canada
Headquarters	100 Spy Court
Employees	16
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Key trends

Past 5 years